Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | AGPAT2 | O15120 | 13/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | POLA1 | P09884 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410666 | 0.91 | NPC1 (0.77) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL14028305 | 0.82 | RAB9A (1.00) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15305715 | 0.81 | RAB9A (0.69) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL30488025 | 0.81 | RAB9A (0.69) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13064960 | 0.79 | POLA1 (0.57) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13880211 | 0.78 | AGPAT2 (1.00) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13880274 | 0.78 | AGPAT2 (1.00) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1886893 | 0.77 | NPC1 (0.62) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13880171 | 0.77 | AGPAT2 (1.00) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13880351 | 0.76 | AGPAT2 (0.72) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | NPC1 3069/4885RAB9A 2538/4885CYP1A2 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.